Navigation Links
Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
Date:10/24/2011

opment and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets.  Its development pipeline of products includes: Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), ASM8 for asthma, PXS25 for idiopathic pulmonary fibrosis and a new oxidase inhibitor for lung disease.  Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

About Bronchitol

Bronchitol has been developed to help clear mucus (a major source of lung infections), improve lung function and reduce exacerbations in patients with cystic fibrosis.

Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be safe, effective, and well tolerated in treating patients cystic fibrosis.

About Cystic Fibrosis

In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway-clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unheal
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
2. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
3. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
4. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
7. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
8. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Many new dentists who are opening ... ensure that their practice will be a success. DentalDisposables.net is ... they use the most can make all the difference. Dentistry ... recently discovered that purchasing discount dental supplies can ... According to successful dentists across the United States ...
(Date:7/24/2014)... 2014  Kinex Pharmaceuticals announced the receipt of an ... Ointment for the commencement of a Phase I clinical ... IND to be allowed by the US FDA in ... synthetic, orally active and highly selective inhibitor of Src ... induction of p53, G2/M arrest of proliferating cell populations ...
(Date:7/24/2014)... 24, 2014 Research and Markets  has ... Market by Product, Component, Application and Geography - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to witness a moderate growth as the markets of ... almost reached the saturation levels. The demand is expected ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
... College of Emergency Physicians 2009 Scientific Assembly ... medical device company developing innovative portable and ... launch of its new palm-sized, affordable ultrasound ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091005/SF86741-a ) , (Logo: ...
... 5 Bausch & Lomb, the global eye health ... of Tubilux Pharma S.p.A. , Tubilux is a privately ... range of proprietary, over-the-counter, and branded generic products primarily ... countries. , Under the terms of the agreement, Bausch ...
Cached Medicine Technology:Signostics Introduces the World's Smallest Ultrasound Product for Global Demands of Affordable Healthcare 2Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 2
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... new study has shown that it is possible to predict ... short-term effects of that same exposure. The findings, which currently ... it possible to develop simpler and cheaper tests to screen ... Despite an overall decrease in incidence of and mortality from ... the disease in their lifetime, and around 20 percent will ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... July 24, 2014 According to ... Business Models, Technology Roadmap, Forecasts and Analysis - ... is expected to reach $7.7 billion by 2018 ... , Browse 102 market data tables and 30 ... on “3D Mapping Market: Global Advancements, Business Models, ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... storage and transport solution formulated ... cells in samples without reducing ... Samples treated with Cyto-Chex can ... seven days prior to analysis ...
... specially designed for use with Coulter® ... package includes diluent, lysing agent, cleaning ... The 15L package configuration includes diluent, ... card. The shelf life is one ...
Medicine Products: